AbbVie Sets Biosimilar Expectations As It Prepares To Take The Plunge On Humira
US Brand Erosion Expected To Be 37% In 2023; Amgen Adalimumab Pricing ‘Not A Surprise’
Executive Summary
AbbVie has set out its expectations for US biosimilar competition to Humira this year, predicting 37% brand erosion with pressures ramping up in the second half of 2023 as Amgen’s Amjevita is followed into the market by numerous other adalimumab rivals. Management also commented on pricing dynamics after Amgen offered a dual-discount strategy.